Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Equity (2016 - 2025)

Historic Return on Equity for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to 0.35%.

  • NovaBay Pharmaceuticals' Return on Equity rose 96500.0% to 0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year increase of 96500.0%. This contributed to the annual value of 0.08% for FY2024, which is 4800.0% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Return on Equity stood at 0.35% for Q3 2025, which was up 96500.0% from 0.06% recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Return on Equity ranged from a high of 14.53% in Q2 2024 and a low of 10.0% during Q3 2024
  • Its 5-year average for Return on Equity is 0.41%, with a median of 0.75% in 2021.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Return on Equity skyrocketed by 277400bps in 2021, and later tumbled by -146000bps in 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Return on Equity (Quarter) stood at 0.6% in 2021, then plummeted by -46bps to 0.87% in 2022, then rose by 14bps to 0.75% in 2023, then decreased by -26bps to 0.95% in 2024, then soared by 64bps to 0.35% in 2025.
  • Its Return on Equity was 0.35% in Q3 2025, compared to 0.06% in Q2 2025 and 0.11% in Q1 2025.